Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series

Wednesday, May 12, 2010 Press Release J E 4
TARRYTOWN, N.Y., May 11 Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in the J. P. Morgan Biotech: CEO/CFO Conference Call Series at 10:00 a.m. Eastern Time on Friday, May 14, 2010.

Conference call details are as follows:

A recording of the call will be available for telephone replay until May 21, 2010.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at

-- Live conference call (US): (888) 889-1309 -- Live conference call (Outside the US): (773) 756-0161 -- Passcode: BIOTECH

SOURCE Regeneron Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Jawa Selects Donor Network of Arizona as First Rec...
WuXi PharmaTech Announces First-Quarter 2010 Resul...